Ann Merrifield - Flexion Therapeutics Director
Director
Ms. Ann Merrifield is an Independent Director of Flexion Therapeutics, Inc. Ms. Merrifield has served as one of our directors since 2014. From December 2012 to July 2014, Ms. Merrifield served as President and Chief Executive Officer of PathoGenetix, Inc., a privately held health genomics company, which voluntarily filed for Chapter 7 bankruptcy in July 2014. Prior to joining PathoGenetix, Inc., Ms. Merrifield served an 18year tenure at Genzyme Corporation, a diversified, global biotechnology company. At Genzyme, Ms. Merrifield served in a number of leadership roles, including as President of Genzyme Biosurgery, where she led global business strategy across a portfolio of biologics, therapeutic devices and combination products, and as President of Genzyme Genetics, where she played an instrumental role in developing and shaping this diagnostic business. Prior to joining Genzyme, Ms. Merrifield was a Partner at Bain and Company, a global strategy consulting firm, and an Investment Officer at Aetna Life Casualty. She currently serves as a director of InVivo Therapeutics Holdings Corporationration, a publicly traded biotechnology company, and as a trustee of MassMutual Premier, Select and MML Series Investment Funds. Ms. Merrifield also served as a director of Juniper Pharmaceuticals, Inc. which was acquired by Catalent, Inc. in 2018 since 2014.
| Age | 67 |
| Tenure | 10 years |
| Professional Marks | MBA |
| Phone | 781 305-7777 |
| Web | www.flexiontherapeutics.com |
Flexion Therapeutics Management Efficiency
The company has return on total asset (ROA) of (18.99) % which means that it has lost $18.99 on every $100 spent on assets. This is way below average. Flexion Therapeutics' management efficiency ratios could be used to measure how well Flexion Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 228.9 M in liabilities. Flexion Therapeutics has a current ratio of 4.52, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Flexion Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Flexion Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Flexion Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Flexion to invest in growth at high rates of return. When we think about Flexion Therapeutics' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Didier Charreton | American Airlines Group | 51 | |
| Jenna Lyons | Shake Shack | 51 | |
| David Elkins | Spirit Airlines | 76 | |
| Spyridon Skiados | Mesa Air Group | 71 | |
| Myrna Soto | Spirit Airlines | 52 | |
| Joshua Silverman | Shake Shack | 51 | |
| Sonia Mason | Mesa Air Group | 44 | |
| Alberto Ibarguen | American Airlines Group | 72 | |
| Daniel Altobello | Mesa Air Group | 76 | |
| Evan Guillemin | Shake Shack | 49 | |
| Don Skiados | Mesa Air Group | 71 | |
| Robert Vivian | Shake Shack | 61 | |
| Matthew Hart | American Airlines Group | 66 | |
| Jerome Kransdorf | The Cheesecake Factory | 79 | |
| Douglas Schmick | The Cheesecake Factory | 67 | |
| Richard Schifter | American Airlines Group | 64 | |
| Noah Elbogen | BJs Restaurants | 35 | |
| Philip Hampton | American Airlines Group | 61 | |
| David Pittaway | The Cheesecake Factory | 66 | |
| Jeffrey Flug | Shake Shack | 58 | |
| Alexander Cappello | The Cheesecake Factory | 62 | |
Management Performance
| Return On Asset | -18.99 |
Flexion Therapeutics Leadership Team
Elected by the shareholders, the Flexion Therapeutics' board of directors comprises two types of representatives: Flexion Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Flexion. The board's role is to monitor Flexion Therapeutics' management team and ensure that shareholders' interests are well served. Flexion Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Flexion Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| David Arkowitz, CFO, Principal Financial Officer and Principal Accounting Officer | ||
| Sandesh Mahatme, Director | ||
| Scott Canute, Director | ||
| Mark Levine, Senior Vice President General Counsel, Secretary | ||
| Kerry Wentworth, Chief Regulatory Officer | ||
| Dan Thornton, Vice President - Market Access | ||
| John Magee, Vice President - Sales | ||
| Neil Bodick, Chief Medical Officer & Co-Founder | ||
| Mark Fraga, Vice President - Marketing | ||
| Michael Clayman, CEO, Co-Founder, Board Member | ||
| Ann Merrifield, Director | ||
| Alan Milinazzo, Independent Director | ||
| Jon Mahlowitz, VP of Legal Affairs | ||
| Frederick Driscoll, CFO and Principal Accounting Officer | ||
| Heath Lukatch, Independent Director | ||
| Christina Willwerth, Chief Strategy Officer | ||
| Patrick Mahaffy, Chairman of the Board | ||
| Samuel Colella, Independent Director | ||
| Yamo Deniz, Chief Medical Officer | ||
| Mark Stejbach, Director | ||
| Scott Kelley, Vice President - Medical Affairs |
Flexion Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Flexion Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -18.99 | |||
| Profit Margin | (92.52) % | |||
| Operating Margin | (71.24) % | |||
| Current Valuation | 408.79 M | |||
| Shares Outstanding | 49.94 M | |||
| Shares Owned By Insiders | 3.58 % | |||
| Shares Owned By Institutions | 92.20 % | |||
| Number Of Shares Shorted | 5.67 M | |||
| Price To Earning | (8.29) X | |||
| Price To Book | 35.88 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest. You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Other Consideration for investing in Flexion Stock
If you are still planning to invest in Flexion Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Flexion Therapeutics' history and understand the potential risks before investing.
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device |